{
  "approved_at_utc": null,
  "subreddit": "stocks",
  "selftext": "Jasper Therapeutics has a promising platform for more effective stem cell transplants and cell therapies. The pipeline is extensive and has a number of notable collaborators (see slide). By their own estimates more effective transplant would expand the market from it’s current \\~4b size to \\~20b (see slide). The company has an EV of roughly \\~250m at this point. For a company of that size, with the potential to unluck another 16b of market cap – the possibility to be a major multi-bagger is evident.\n\nSo what are the catalysts? \n\n(a) Amgen (AMGN, 120B market cap) recently disclosed a major stake (7% of the company), so clearly they see some major potential here.\n\nhttps://www.sec.gov/Archives/edgar/data/318154/000119312521289912/d79598dsc13g.htm\n\n(b) There is a number of catalysts (see slide) that should occur before year\n\n(c) The float seems to be exceptionally tight. Perhaps it only \\~700k-4m at this point. The stock has been trading oddly and seem a number of halts on practically no volume.\n\nMy thesis is that as more serious traders re-evaluate the company in light of the AMGM position and PR’s are released as they check of these milestones – given the tight float it could run rather hard. \n\nReferenced slides are here\n\n[https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2\\_amplitude.htm](https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2_amplitude.htm)",
  "author_fullname": "t2_31rrp",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 1,
  "clicked": false,
  "title": "JSPR - stem cell bio with major buy-in from AMGN",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/stocks",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": "tickernews",
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_q21jy9",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.98,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 149,
  "total_awards_received": 4,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": "Company News",
  "can_mod_post": false,
  "score": 149,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": true,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {
    "gid_2": 1
  },
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1633455756,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.stocks",
  "allow_live_comments": true,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Jasper Therapeutics has a promising platform for more effective stem cell transplants and cell therapies. The pipeline is extensive and has a number of notable collaborators (see slide). By their own estimates more effective transplant would expand the market from it’s current ~4b size to ~20b (see slide). The company has an EV of roughly ~250m at this point. For a company of that size, with the potential to unluck another 16b of market cap – the possibility to be a major multi-bagger is evident.</p>\n\n<p>So what are the catalysts? </p>\n\n<p>(a) Amgen (AMGN, 120B market cap) recently disclosed a major stake (7% of the company), so clearly they see some major potential here.</p>\n\n<p><a href=\"https://www.sec.gov/Archives/edgar/data/318154/000119312521289912/d79598dsc13g.htm\">https://www.sec.gov/Archives/edgar/data/318154/000119312521289912/d79598dsc13g.htm</a></p>\n\n<p>(b) There is a number of catalysts (see slide) that should occur before year</p>\n\n<p>(c) The float seems to be exceptionally tight. Perhaps it only ~700k-4m at this point. The stock has been trading oddly and seem a number of halts on practically no volume.</p>\n\n<p>My thesis is that as more serious traders re-evaluate the company in light of the AMGM position and PR’s are released as they check of these milestones – given the tight float it could run rather hard. </p>\n\n<p>Referenced slides are here</p>\n\n<p><a href=\"https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2_amplitude.htm\">https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2_amplitude.htm</a></p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "link_flair_template_id": "5a4c814a-65e6-11e5-b65e-122ab0778f8b",
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qjfk",
  "author_is_blocked": false,
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "#f9cc80",
  "id": "q21jy9",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "joeskunk",
  "discussion_type": null,
  "num_comments": 26,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/",
  "subreddit_subscribers": 3096890,
  "created_utc": 1633488226,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1633455756,
  "the_new_excerpt": "Jasper Therapeutics has a promising platform for more effective stem cell\ntransplants and cell therapies. The pipeline is extensive and has a number of\nnotable collaborators (see slide). By their own estimates more effective\ntransplant would expand the market from it’s current ~4b size to ~20b…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "ジャスパー・セラピューティック社は、より効果的な幹細胞移植のための有望なプラットフォームを持っています。\nより効果的な幹細胞移植と細胞治療のための有望なプラットフォームを持っています。パイプラインは充実しており、注目すべき共同研究者も多数います。\n注目すべき共同研究者がいます（スライド参照）。彼らの推計によると、より効果的な\n移植がより効果的になれば、市場規模は現在の約40億円から約200億円に拡大します。",
      "title": "JSPR - AMGNが買収した幹細胞バイオ企業"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "Jasper Therapeutics为更有效的干细胞移植和细胞治疗提供了一个很有前景的平台。\n移植和细胞治疗。该公司的管线非常广泛，并有许多著名的合作者。\n显著的合作者（见幻灯片）。根据他们自己的估计,更有效的\n移植将使市场从目前约40亿规模扩大到约200亿。",
      "title": "JSPR--干细胞生物，得到AMGN的重大收购。"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "Jasper Therapeutics爲更有效的幹細胞移植和細胞治療提供了一個很有前景的平臺。\n移植和細胞治療。該公司的管線非常廣泛，並有許多著名的合作者。\n顯著的合作者（見幻燈片）。根據他們自己的估計,更有效的\n移植將使市場從目前約40億規模擴大到約200億。",
      "title": "JSPR--幹細胞生物，得到AMGN的重大收購。"
    }
  ],
  "source_updated_at": 1633685996310
}